Clinical Application of Thyrotropin Receptor Antibodies

Abstract

Thyrotropin receptor antibodies (TRAb) are specific for Graves’ disease (GD) and play a crucial role in the pathogenesis of GD. TRAb assays have recently been greatly improved. This review discusses the clinical application of TRAb in the differential diagnosis of hyperthyroidism, the prognosis of GD, GD in gestation and pediatrics, and GD related ophthalmopathy (GO). In addition to the classical competition and bioassays, a new bridging assay has emerged for TRAb assays. TRAb is the main pathogenic mechanism of hyperthyroidism in GD. Treated GD still has a high rate of recurrence and even a short-term surge of TRAb, leading to rapid deterioration of GO. Fetal goiter may be associated with elevated maternal TRAb during pregnancy, overtreatment may lead to fetal hypothyroidism. Pediatric patients with GD have high TRAb, poor remission from treatment, and insignificant manifestations of GO. TRAb is significantly correlated with GO activity and severity. Currently, TRAb assay has high specificity and sensitivity and can be used directly to identify the cause of hyperthyroidism. TRAb can be used to predict recurrence of drug treated GD or progression of GO after RAI therapy. TRAb should be measured regularly for GD in gestation to guide anti-thyroid medication to avoid thyrotoxicosis or hypothyroidism in the fetus. Monitoring TRAb in pediatric GD may help control the progression of GO. TRAb assay is an important guide for the treatment of GO.

Keywords

Graves’ disease - TRAb - diagnosis - prognosis

Publikationsverlauf

Eingereicht: 25. Oktober 2024

Angenommen nach Revision: 09. Dezember 2024

Accepted Manuscript online:
09. Dezember 2024

Artikel online veröffentlicht:
10. Februar 2025

• References

• 1 Wiersinga WM, Poppe KG, Effraimidis G. Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis. Lancet Diabetes Endocrinol 2023; 11: 282-298
• 2 Davies TF, Andersen S, Latif R. et al. Graves’ disease. Nat Rev Dis Primers 2020; 6: 52
• 3 Smith TJ, Hegedüs L. Graves’ disease. N Engl J Med 2016; 375: 1552-1565
• 4 Brandt F, Thvilum M, Almind D. et al. Graves’ disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish populationbased register study. Thyroid 2013; 23: 408-413
• 5 Dekkers OM, Horváth-Puhó E, Cannegieter SC. et al. Acute cardiovascular events and allcause mortality in patients with hyperthyroidism: a populationbased cohort study. Eur J Endocrinol 2017; 176: 1-9
• 6 Biondi B, Kahaly GJ, Robertson RP. Thyroid dysfunction and diabetes mellitus: two closely associated disorders. Endocr Rev 2019; 40: 789-824
• 7 Bolf EL, Sprague BL, Carr FE. A linkage between thyroid and breast cancer: a common etiology?. Cancer Epidemiol Biomarkers Prev 2019; 28: 643-649
• 8 Lillevang-Johansen M, Abrahamsen B, Jørgensen HL. et al. Excess mortality in treated and untreated hyperthyroidism is related to cumulative periods of low serum TSH. J Clin Endocrinol Metab 2017; 102: 2301-2309
• 9 Adams DD, Purves HD. Abnormal responses in the assay of thyrotropins. Proc Univ Otago Med School 1956; 34: 11-12
• 10 Martin A, Barbesino G, Davies TF. T-cell receptors and autoimmune thyroid disease--signposts for T-cell-antigen driven diseases. Int Rev Immunol 1999; 18: 111-140
• 11 Chen CR, Pichurin P, Nagayama Y. et al. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. J Clin Invest 2003; 111: 1897-1904
• 12 Sanders J, Chirgadze DY, Sanders P. et al. Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody. Thyroid 2007; 17: 395-410
• 13 Sanders P, Young S, Sanders J. et al. Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody. J Mol Endocrinol 2011; 46: 81-99
• 14 Morshed SA, Latif R, Davies TF. Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology 2009; 150: 519-529
• 15 McLachlan SM, Rapoport B. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. Thyroid 2013; 23: 14-24
• 16 Morshed SA, Davies TF. Graves’ disease mechanisms: the role of stimulating, blocking, and cleavage region TSH receptor antibodies. Horm Metab Res 2015; 47: 727-734
• 17 Morshed SA, Ando T, Latif R. et al. Neutral antibodies to the TSH receptor are present in Graves’ disease and regulate selective signaling cascades. Endocrinology 2010; 151: 5537-5549
• 18 Stassi G, De Maria R. Autoimmune thyroid disease: new models of cell death in autoimmunity. Nat Rev Immunol 2002; 2: 195-204
• 19 Ovčariček PP, Görges R, Giovanella L. Autoimmune thyroid diseases. Semin Nucl Med 2024; 54: 219-236
• 20 Tozzoli R, Bagnasco M, Giavarina D. et al. TSH receptor autoantibody immunoassay in patients with Graves’ disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. Autoimmun Rev 2012; 12: 107-113
• 21 Barbesino G, Tomer Y. Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab 2013; 98: 2247-2255
• 22 Smith BR, Bolton J, Young S. et al. A new assay for thyrotropin receptor autoantibodies. Thyroid 2004; 14: 830-835
• 23 Schott M, Hermsen D, Broecker-Preuss M. et al. Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves’ disease (GD): an international multicentre trial. Clin Endocrinol (Oxf) 2009; 71: 566-573
• 24 Hinds WE, Takai N, Rapoport B. et al. Thyroid-stimulating immunoglobulin bioassay using cultured human thyroid cells. J Clin Endocrinol Metab 1981; 52: 1204-1210
• 25 Lytton SD, Ponto KA, Kanitz M. et al. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy. J Clin Endocrinol Metab 2010; 95: 2123-2131
• 26 Gao YM, Qiu L, Yu SL. et al. Thyroid stimulating receptor autoantibodies. Clin Chim Acta 2024; 559: 119700
• 27 Frank CU, Braeth S, Dietrich JW. et al. Bridge technology with TSH receptor chimera for sensitive direct dDetection of TSH receptor antibodies causing Graves’ disease: analytical and clinical evaluation. Horm Metab Res 2015; 47: 880-888
• 28 Ehlers M, Schott M, Allelein S. Graves’ disease in clinical perspective. Front Biosci 2019; 24: 35-47
• 29 Kim JJ, Jeong SH, Kim B. et al. Analytical and clinical performance of newly developed immunoassay for detecting thyroid-stimulating immunoglobulin, the Immulite TSI assay. Scand J Clin Lab Invest 2019; 79: 443-448
• 30 Allelein S, Diana T, Ehlers M. et al. Comparison of a bridge immunoassay with two bioassays for thyrotropin receptor antibody detection and differentiation. Horm Metab Res 2019; 51: 341-346
• 31 Kahaly GJ, Bartalena L, Hegedüs L. The American thyroid association/American association of clinical endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective. Thyroid 2011; 21: 585-591
• 32 Ross DS, Burch HB, Cooper DS. et al. 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016; 26: 1343-1421
• 33 Zöphel K, Roggenbuck D, Schott M. Clinical review about TRAb assay’s history. Autoimmun Rev 2010; 9: 695-700
• 34 Rosario PW. Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU/l: a prospective study. Clin Endocrinol (Oxf) 2010; 72: 685-688
• 35 Laurberg P, Wallin G, Tallstedt L. et al. TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008; 158: 69-75
• 36 Piantanida E, Lai A, Sassi L. et al. Outcome prediction of treatment of Graves’ hyperthyroidism with antithyroid drugs. Horm Metab Res 2015; 47: 767-772
• 37 Dwivedi SK, Kalaria T, Buch H. Thyroid autoantibodies. J Clin Pathol 2023; 76: 19-28
• 38 Kotwal A, Stan M. Thyrotropin receptor antibodies – an overview. Ophthalmic Plast Reconstr Surg 2018; 34: S20-S27
• 39 Chaker L, Cooper SD, Walsh JP. et al. Hyperthyroidism. Lancet 2024; 403: 768-780
• 40 Kahaly GJ. Management of Graves thyroidal and extrathyroidal disease: an update. J Clin Endocrinol Metab 2020; 105: 3704-3720
• 41 Lee SY, Pearce EN. Testing, monitoring, and treatment of thyroid dysfunction in pregnancy. J Clin Endocrinol Metab 2021; 106: 883-892
• 42 Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol 2013; 1: 238-249
• 43 Lee SY, Pearce EN. Assessment and treatment of thyroid disorders in pregnancy and the postpartum period. Nat Rev Endocrinol 2022; 18: 158-171
• 44 Wang MT, Lee WJ, Huang TY. et al. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J Clin Pharmacol 2014; 78: 619-629
• 45 Suzuki N, Noh JY, Hiruma M. et al. Analysis of antithyroid drug-induced severe liver injury in 18,558 newly diagnosed patients with Graves’ disease in Japan. Thyroid 2019; 29: 1390-1398
• 46 Andersen SL, Olsen J, Wu CS. et al. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab 2013; 98: 4373-4381
• 47 Nguyen CT, Mestman HJ. Graves’ hyperthyroidism in pregnancy. Curr Opin Endocrinol Diabetes Obes 2019; 26: 232-240
• 48 Kobaly K, Mandel SJ. Hyperthyroidism and pregnancy. Endocrinol Metab Clin North Am 2019; 48: 533-545
• 49 Alexander EK, Pearce EN, Brent GA. et al. 2017 Guidelines of the American thyroid association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 2017; 27: 315-389
• 50 Quintanilla-Dieck L, Khalatbari HK, Dinauer CA. et al. Management of pediatric Graves disease: a review. JAMA Otolaryngol Head Neck Surg 2021; 147: 1110-1118
• 51 van der Kaay DC, Wasserman JD, Palmert MR. Management of neonates born to mothers with Graves’ Disease. Pediatrics 2016; 137: e20151878
• 52 Obeid R, Obeid R, Kalra VK. et al. Neonatal thyrotoxicosis presenting as persistent pulmonary hypertension. BMJ Case Rep 2012; bcr0220125939
• 53 Regelmann MO, Sullivan CK, Rapaport R. Thyroid “vise” in an infant with neonatal Graves’ disease. Pediatrics 2013; 132: e1048-e1051
• 54 Kaplowitz PB, Vaidyanathan P. Update on pediatric hyperthyroidism. Curr Opin Endocrinol Diabetes Obes 2020; 27: 70-76
• 55 Banigé M, Estellat C, Biran V. et al. Study of the factors leading to fetal and neonatal dysthyroidism in children of patients with Graves Disease. J Endocr Soc 2017; 1: 751-761
• 56 De Luca F, Alessi L, Bruno E. et al. Graves’ disease in childhood: new epidemiological, pathophysiological and therapeutic insights. Minerva Pediatr 2016; 68: 66-69
• 57 Wiersinga W, Žarković M, Bartalena L. et al. Predictive score for the development or progression of Graves’ orbitopathy in patients with newly diagnosed Graves’ hyperthyroidism. Eur J Endocrinol 2018; 178: 635-643
• 58 Taylor PN, Zhang L, Lee RWJ. et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol 2020; 16: 104-116
• 59 Rotondo DG, Torregrossa L, Caturegli P. et al. Association of T and B cells infiltrating orbital tissues with clinical features of Graves orbitopathy. JAMA Ophthalmol 2018; 136: 613-619
• 60 Pawlowski P, Reszec J, Eckstein A. et al. Markers of inflammation and fibrosis in the orbital fat/connective tissue of patients with Graves’ orbitopathy: clinical implications. Mediators Inflamm 2014; 412158
• 61 Cao J, Su Y, Chen Z. et al. The risk factors for Graves’ ophthalmopathy. Graefes Arch Clin Exp Ophthalmol 2022; 260: 1043-1054
• 62 Zhang L, Grennan-Jones F, Draman MS. et al. Possible targets for nonimmunosuppressive therapy of Graves’ orbitopathy. J Clin Endocrinol Metab 2014; 99: E1183-E1190
• 63 Krieger CC, Place RF, Bevilacqua C. et al. TSH/IGF-1 receptor cross talk in Graves’ ophthalmopathy pathogenesis. J Clin Endocrinol Metab 2016; 101: 2340-2347
• 64 Krieger CC, Neumann S, Place RF. et al. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves’ disease immunoglobins. J Clin Endocrinol Metab 2015; 100: 1071-1077
• 65 Bartalena L, Tanda ML. Current concepts regarding Graves’ orbitopathy. J Intern Med 2022; 292: 692-716
• 66 Ryder M, Wentworth M, Algeciras-Schimnich A. et al. Blocking the thyrotropin receptor with K1-70 in a patient with follicular thyroid cancer, Graves’ disease, and Graves’ ophthalmopathy. Thyroid 2021; 31: 1597-1602
• 67 Furmaniak J, Sanders J, Sanders P. et al. TSH receptor specific monoclonal autoantibody K1-70^TM targeting of the TSH receptor in subjects with Graves' disease and Graves’ orbitopathy – results from a phase I clinical trial. Clin Endocrinol (Oxf) 2022; 96: 878-887